Search

everythinglearnresearchcommunity

for

Search:↓

5-alpha reductase inhibitors can cause sexual side effects like erectile dysfunction and reduced sexual desire, sometimes lasting after stopping the drug.

Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.

Dutasteride effectively treats enlarged prostate, reduces prostate cancer risk, and promotes hair regrowth with few side effects.

5-alpha reductase inhibitors slightly increase the risk of sexual and mood side effects, and breast growth in men.

There is no strong evidence that chemopreventive agents effectively prevent prostate cancer.

Men with less sun-sensitive skin have lower PSA levels, while men with more sun-sensitive skin have higher PSA levels.

Peripheral treatments showed some improvement in sexual dysfunction, but central symptoms remain challenging.

Four genetic risk spots found for hair loss, with WNT signaling involved and a link to curly hair.

Genetic differences within ethnic groups may affect prostate cancer treatment effectiveness.

Medications for benign prostatic syndrome can cause cognitive issues and depression.

5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.

Finasteride reduces urinary issues and surgery need in men with enlarged prostates by over 50%.

Finasteride effectively treats BPH but may increase sexual dysfunction risk.

Testosterone therapy increases bone density in older men with low testosterone levels.

5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.

The questionnaire effectively measures men's perceived hair growth and can distinguish between different treatments and dosages.

Taking 5-α reductase inhibitors for prostate enlargement or hair loss does not significantly raise the risk of erectile dysfunction.

Finasteride use doesn't cause sexual dysfunction in men with hair loss.

TURP is the best treatment for BPH, but some patients prefer medications like alpha-blockers and finasteride.

Baldness in men with prostate cancer is linked to higher levels of certain sex hormones, but chest hair density is not.

Higher levels of miR-1199-5p may reduce the effectiveness of certain prostate treatments.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

Platelet-rich plasma shows promise in reducing pain for bladder pain syndrome.

Combination therapy for 9+ months maintains symptom improvements after stopping alpha-blockers or finasteride.

Early diagnosis and treatment of Hidradenitis Suppurativa are important to prevent serious physical and mental effects.

New method measures finasteride in plasma, finds two formulations bioequivalent.

Finasteride effectively reduces prostate size and symptoms in most BPH patients.

Systematic end-of-trial biopsies are the most reliable way to assess outcomes.

COVID-19 can harm male fertility by reducing sperm stem cells and damaging testicular function.